|The CD276 cd276 (Catalog #MBS606354) is an Antibody produced from Mouse
Source: Human and is intended for research purposes only. The product is available for immediate purchase. The Anti - CD276 (4Ig-B7-H3, B7 Homolog 3, B7-H3, B7H3, CD276 Antigen, CD276 Molecule, Costimulatory Molecule) (FITC) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s CD276 can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry.
Suitable for use in Flow Cytometry. Other applications not tested.
Dilution: Flow Cytometry: Neat; 10ul labels 10e6 cells in 100ul
Optimal dilutions to be determined by the researcher. Researchers should empirically determine the suitability of the CD276 cd276 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CD276 cd276 product has the following accession number(s) (GI #67188443) (NCBI Accession #NP_001019907.1) (Uniprot Accession #Q5ZPR3). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3. CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma. Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon. In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing. CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.
Immunogen: Human CD276. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD276 are readily searchable from our website. Different antibodies against the same target such as CD276 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. The following patways have been known to be associated with this gene. Breast Neoplasms, Carcinoma, Inflammation, Liver Diseases, Liver Neoplasms, Lung Neoplasms, Necrosis, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms are some of the diseases may be linked to Anti - CD276 (4Ig-B7-H3, B7 Homolog 3, B7-H3, B7H3, CD276 Antigen, CD276 Molecule, Costimulatory Molecule) (FITC).